Chondroitin Sulfate Alleviates Diabetic Osteoporosis and Repairs Bone Microstructure Anti-Oxidation, Anti-Inflammation, and Regulating Bone Metabolism

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2021 Nov 15

PMID 34777254

Citations 11

Authors

Shan Shan Qi

Meng Li Shao

Ze Sun

Si Min Chen

Ying Jun Hu

Xin Sheng Li

De Jing Chen

Hong Xing Zheng

Tian Li Yue

Affiliations

Soon will be listed here.

Abstract

Diabetic osteoporosis (DOP) belongs to secondary osteoporosis caused by diabetes; it has the characteristics of high morbidity and high disability. In the present study, we constructed a type 1 diabetic rat model and administered chondroitin sulfate (200 mg/kg) for 10 weeks to observe the preventive effect of chondroitin sulfate on the bone loss of diabetic rats. The results showed that chondroitin sulfate can reduce blood glucose and relieve symptoms of diabetic rats; in addition, it can significantly increase the bone mineral density, improve bone microstructure, and reduce bone marrow adipocyte number in diabetic rats; after 10 weeks of chondroitin sulfate administration, the SOD activity level was upregulated, as well as CAT levels, indicating that chondroitin sulfate can alleviate oxidative stress in diabetic rats. Chondroitin sulfate was also found to reduce the level of serum inflammatory cytokines (TNF-α, IL-1, IL-6, and MCP-1) and alleviate the inflammation in diabetic rats; bone metabolism marker detection results showed that chondroitin sulfate can reduce bone turnover in diabetic rats (decreased RANKL, CTX-1, ALP, and TRACP 5b levels were observed after 10 weeks of chondroitin sulfate administration). At the same time, the bone OPG and RUNX 2 expression levels were higher after chondroitin sulfate treatment, the bone RANKL expression was lowered, and the OPG/RANKL ratio was upregulated. All of the above indicated that chondroitin sulfate could prevent STZ-induced DOP and repair bone microstructure; the main mechanism was through anti-oxidation, anti-inflammatory, and regulating bone metabolism. Chondroitin sulfate could be used to develop anti-DOP functional foods and diet interventions for diabetes.

Citing Articles

Network Pharmacology and Experimental Validation of the Therapeutic Effect of Baji Capsule on LPS-Induced Osteoporosis.

Li Q, Li D, Tian C, Liu X, Wang H, Liu H Orthop Res Rev. 2025; 17:61-81.

PMID: 39958436 PMC: 11829595. DOI: 10.2147/ORR.S488478.

Eggshell membrane as promising supplement to maintain bone health: A systematic review.

Fladerer J, Grollitsch S Bone Rep. 2024; 21:101776.

PMID: 38872992 PMC: 11170356. DOI: 10.1016/j.bonr.2024.101776.

Intervention effects of low-molecular-weight chondroitin sulfate from the nasal cartilage of yellow cattle on lipopolysaccharide-induced behavioral disorders: regulation of the microbiome-gut-brain axis.

Deng Y, Li Q, Song J, Guo R, Ma T, Liu Z Front Nutr. 2024; 11:1371691.

PMID: 38835960 PMC: 11148680. DOI: 10.3389/fnut.2024.1371691.

Identification of cell-specific epigenetic patterns associated with chondroitin sulfate treatment response in an endemic arthritis, Kashin-Beck disease.

Cheng B, Wu C, Wei W, Niu H, Wen Y, Li C Bone Joint Res. 2024; 13(5):237-246.

PMID: 38754865 PMC: 11098597. DOI: 10.1302/2046-3758.135.BJR-2023-0271.R1.

Mg-ZIF nanozyme regulates the switch between osteogenic and lipogenic differentiation in BMSCs via lipid metabolism.

Li J, Chen Y, Zha D, Wu C, Li X, Yang L Lipids Health Dis. 2024; 23(1):88.

PMID: 38528544 PMC: 10962101. DOI: 10.1186/s12944-024-02083-3.

References

Palui R, Pramanik S, Mondal S, Ray S . Critical review of bone health, fracture risk and management of bone fragility in diabetes mellitus. World J Diabetes. 2021; 12(6):706-729. PMC: 8192255. DOI: 10.4239/wjd.v12.i6.706. View

Kim T, Schafer A . Diabetes and Bone Marrow Adiposity. Curr Osteoporos Rep. 2016; 14(6):337-344. PMC: 5126977. DOI: 10.1007/s11914-016-0336-x. View

Noh J, Yang Y, Jung H . Molecular Mechanisms and Emerging Therapeutics for Osteoporosis. Int J Mol Sci. 2020; 21(20). PMC: 7589419. DOI: 10.3390/ijms21207623. View

Li X, Zhu Z, Han S, Zhang Z . Bergapten exerts inhibitory effects on diabetes-related osteoporosis via the regulation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways in osteoprotegerin knockout mice. Int J Mol Med. 2016; 38(6):1661-1672. PMC: 5117769. DOI: 10.3892/ijmm.2016.2794. View

Taylor G, Moser O, Smith K, Shaw A, Tang J, Fraser W . Bone turnover and metabolite responses to exercise in people with and without long-duration type 1 diabetes: a case-control study. BMJ Open Diabetes Res Care. 2020; 8(2). PMC: 7643495. DOI: 10.1136/bmjdrc-2020-001779. View

Wang W, Bai J, Zhang W, Ge G, Wang Q, Liang X . Protective Effects of Punicalagin on Osteoporosis by Inhibiting Osteoclastogenesis and Inflammation the NF-κB and MAPK Pathways. Front Pharmacol. 2020; 11:696. PMC: 7242619. DOI: 10.3389/fphar.2020.00696. View

Pudelko A, Wisowski G, Olczyk K, Kozma E . The dual role of the glycosaminoglycan chondroitin-6-sulfate in the development, progression and metastasis of cancer. FEBS J. 2019; 286(10):1815-1837. PMC: 6850286. DOI: 10.1111/febs.14748. View

Kamusheva M, Tachkov K, Dimitrova M, Mitkova Z, Garcia-Saez G, Elena Hernando M . A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care. Front Endocrinol (Lausanne). 2021; 12:636959. PMC: 8008960. DOI: 10.3389/fendo.2021.636959. View

Wen Y, Li H, Zhang X, Liu P, Ma J, Zhang L . Correlation of Osteoporosis in Patients With Newly Diagnosed Type 2 Diabetes: A Retrospective Study in Chinese Population. Front Endocrinol (Lausanne). 2021; 12:531904. PMC: 8160464. DOI: 10.3389/fendo.2021.531904. View

10.

Gomes C, Leao C, Venturotti C, Barreira A, Guimaraes G, Fonseca R . The protective role of fucosylated chondroitin sulfate, a distinct glycosaminoglycan, in a murine model of streptozotocin-induced diabetic nephropathy. PLoS One. 2014; 9(9):e106929. PMC: 4156394. DOI: 10.1371/journal.pone.0106929. View

11.

Aviles-Santa M, Monroig-Rivera A, Soto-Soto A, Lindberg N . Current State of Diabetes Mellitus Prevalence, Awareness, Treatment, and Control in Latin America: Challenges and Innovative Solutions to Improve Health Outcomes Across the Continent. Curr Diab Rep. 2020; 20(11):62. PMC: 7546937. DOI: 10.1007/s11892-020-01341-9. View

12.

Zhao Y, Wang H, Li T, Yang F, Tzeng C . Baicalin Ameliorates Dexamethasone-Induced Osteoporosis by Regulation of the RANK/RANKL/OPG Signaling Pathway. Drug Des Devel Ther. 2020; 14:195-206. PMC: 6970258. DOI: 10.2147/DDDT.S225516. View

13.

Verges J, Montell E, Herrero M, Perna C, Cuevas J, Perez M . Clinical and histopathological improvement of psoriasis with oral chondroitin sulfate: a serendipitous finding. Dermatol Online J. 2005; 11(1):31. View

14.

Owen M, Baker B, Scott E, Forbes K . Interaction between Metformin, Folate and Vitamin B and the Potential Impact on Fetal Growth and Long-Term Metabolic Health in Diabetic Pregnancies. Int J Mol Sci. 2021; 22(11). PMC: 8198407. DOI: 10.3390/ijms22115759. View

15.

Qi S, He J, Zheng H, Chen C, Lan S . Icariin Prevents Diabetes-Induced Bone Loss in Rats by Reducing Blood Glucose and Suppressing Bone Turnover. Molecules. 2019; 24(10). PMC: 6571757. DOI: 10.3390/molecules24101871. View

16.

Iacobini C, Vitale M, Pesce C, Pugliese G, Menini S . Diabetic Complications and Oxidative Stress: A 20-Year Voyage Back in Time and Back to the Future. Antioxidants (Basel). 2021; 10(5). PMC: 8147954. DOI: 10.3390/antiox10050727. View

17.

Ma R, Zhu R, Wang L, Guo Y, Liu C, Liu H . Diabetic Osteoporosis: A Review of Its Traditional Chinese Medicinal Use and Clinical and Preclinical Research. Evid Based Complement Alternat Med. 2016; 2016:3218313. PMC: 5028800. DOI: 10.1155/2016/3218313. View

18.

Azizieh F, Shehab D, Jarallah K, Gupta R, Raghupathy R . Circulatory Levels of RANKL, OPG, and Oxidative Stress Markers in Postmenopausal Women With Normal or Low Bone Mineral Density. Biomark Insights. 2019; 14:1177271919843825. PMC: 6700864. DOI: 10.1177/1177271919843825. View

19.

Coe L, Irwin R, Lippner D, McCabe L . The bone marrow microenvironment contributes to type I diabetes induced osteoblast death. J Cell Physiol. 2010; 226(2):477-83. DOI: 10.1002/jcp.22357. View

20.

Melgar-Lesmes P, Garcia-Polite F, Del-Rey-Puech P, Rosas E, Dreyfuss J, Montell E . Treatment with chondroitin sulfate to modulate inflammation and atherogenesis in obesity. Atherosclerosis. 2015; 245:82-7. PMC: 4738029. DOI: 10.1016/j.atherosclerosis.2015.12.016. View